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ABSTRACT  Damage to small blood vessels in diabetes mellitus (DM) is largely the result of 
hyperglycemia-driven oxidative stress. This is manifested morphologically by capillary 
basement membrane (BM) thickening, the hallmark feature of chronic complications of 
DM.  In an effort to demonstrate pulmonary alveolar BM (PABM) thickness increase in 
DM and to demonstrate for the first time, mitigation of the increase utilizing antioxidant 
therapy, we crossed the severely diabetic transgenic mouse (OVE) with Jtmt, our recently 
developed transgenic animal model that overexpresses the antioxidant metallothionein 
(MT) in endothelial cells. Unbiased TEM morphometry demonstrated that PABM widths 
in diabetic (OVE) mice were significantly (+20%) thickened. Remarkably, however, the 
bi-transgenic OVEJtmt progney exhibited statistically significant protection against DM-
derived BM thickening. These results provide evidence for a direct role of oxidative 
damage to endothelial cells in diabetic mice and show that protection of these cells can 
reduce one of the primary features of diabetic microangiopathy. 
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CHAPTER I 
INTRODUCTION 
 Diabetes mellitus (DM) is a serious and potentially debilitating disease that is 
considered an epidemic in the Western hemisphere including the United States where 
approximately 8.3% of the population is diabetic (Center for Disease Control, 2011). In 
2000, more than 171 million people were afflicted with the disease worldwide and it is 
anticipated that by the year 2030, more than 366 million people will be diagnosed (Wild 
et al., 2004; WHO, 2006). Importantly, by 2030, DM is predicted to be the seventh 
leading cause of death in the U.S. due to the serious vascular complications that 
accompany it (WHO, 2006). Extensive research has been carried out in an effort to 
eliminate DM and to mitigate its chronic complications. Nevertheless, additional studies 
will be required to understand the causes of DM and reduce the escalating number of 
diagnoses and increased health care costs each year.  
 Diabetes is characterized as a group of metabolic diseases, in which 
hyperglycemia and glucose intolerance transpire, which results in diseased 
microvasculature. The two main types of DM are Type I (T1D) and Type II (T2D). Each 
is characterized by chronic hyperglycemia as well as deregulated metabolism of fats, 
proteins, and carbohydrates (McCance and Heuther, 2010).  
 Type I DM is an autoimmune condition caused by malfunctioning primary 
pancreatic beta cells. This condition is also known as Insulin-Dependent Diabetes (IDD) 
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because the pancreas produces and secretes insufficient amounts of insulin (Jahromi and 
Eisenbarth, 2007). Accordingly, diabetic patients depend on synthetic insulin for 
maintenance of appropriate serum blood sugar and survival (Jahromi and Eisenbarth, 
2007). Type I diabetes accounts for approximately 10% of all diagnosed cases, and its 
incidence has nearly doubled over the past twenty years (Nokoff and Rewers, 2013). In 
the United States, individuals under the age of 20 are especially at risk of developing 
T1D, as shown by an increase in diagnoses in this age group by 23% between 2001 and 
2009 (Nokoff and Rewers, 2013). It is hypothesized that this increase is correlated to the 
epidemic of childhood obesity. 
 Within the Type I class, there are two subcategories: autoimmune diabetes 
[type 1A (T1A)] and nonimmune diabetes [type 1B (T1B)] (Jahromi and Eisenbarth, 
2007). Type 1B diabetes, also known as idiopathic diabetes, often occurs as a secondary 
condition initiated by other ailments affecting the pancreas, such as pancreatitis, 
neoplasia, and cystic fibrosis (McCance and Heuther, 2010). Type 1A diabetes is more 
common than T1B and is triggered by a combination of genetic and environmental 
factors resulting in the overproduction of autoantibodies that destroy pancreatic beta cells 
(Jahromi and Eisenbarth, 2007).  
 Environmental factors that have been strongly correlated with the cause of T1D 
include viral infections such as: mumps, enteroviruses, endogenous retroviruses, 
parvovirus, rotovirus, cytomegalovirus, and congenital rubella (Richer and Horwitz, 
2008), drugs and chemicals such as: streptozotocin, alloxan, pentamidine, and vacor, 
(McCance and Heuther, 2010) and dietary factors such as, bovine milk and cereal 
(Jahromi and Eisenbarth, 2007). 
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 In addition to environmental contributors, a strong link between specific genetic 
backgrounds and the development of autoimmune diseases, including T1D, have been 
made. The histocompatibility leukocyte antigen (HLA) and its associated genetic variants 
have been the most compelling risk factor in familial diabetic cases (Nokoff and Rewers, 
2013). 
 Type II diabetes is by far the most common type of diabetes, and accounts for  
90-95% of diagnosed cases (Nokoff and Rewers, 2013). Onset of T2D often occurs later 
in life, with an average age between 45-64 years. Incidence rates are increasing in all age 
groups in the United States, and the risk of developing the disease increases after the age 
of 40 (McCance and Heuther, 2010). Obesity significantly increases the risk for 
developing the disease and the risk is related to the duration, degree, and distribution of 
obesity (McCance and Heuther, 2010). The major distinction between T2D and T1D is 
the development of insulin resistance in T2D, as well as decreased insulin secretion over 
the duration of the illness (Wright et al., 2006).  
 Genetic predisposition, age, and other environmental factors contribute to the risk 
of developing DM and treating its inevitable complications is essential. The 
pathophysiology of these complications must be understood because the increasing 
morbidity and mortality of DM is caused by the associated chronic complications in the 
macro- and microvasculature (Sheetz, 2002).  
Chronic Complications of Diabetes Mellitus 
 Insulin resistance and chronic hyperglycemia have been implicated in the 
pathogenesis of chronic complications associated with DM (Brownlee, 2001). Chronic 
complications of DM are serious pathological states associated with the condition that 
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contribute to significantly increased health care costs and major obstacles in diabetes 
therapy. The most common chronic complications include; diabetic nephropathy, diabetic 
cardiomyopathy, diabetic neuropathy, and diabetic retinopathy.  
 Macrovascular complications occur when arteries supplying the brain, heart, and 
lower extremities become atherosclerotic (Brownlee, 2001). Diseased large vessels 
contribute to the fact that diabetic patients have an increased incidence of myocardial 
infarction, stroke, and lower limb amputation (Brownlee, 2001). Microvascular 
complications are pathological states of smaller blood vessels supplying the retina, 
kidneys, and peripheral nerves. Atherosclerotic microvasculature is a major cause of 
blindness, end stage renal disease, and peripheral nerve damage in many diabetic patients 
(Brownlee, 2001). 
 Interestingly, a unifying pathophysiological change in these chronic 
complications is the thickening of basement membranes (BM) - a specialized component 
of the extracellular matrix (ECM) associated with all non-connective tissues including the 
endothelium of the macro- and microvasculature (Ozsahin et al., 2006).  
The Extracellular Matrix and Diabetic Induced Alterations 
 The ECM is a biophysical component of cellular networks that maintains 
structural and mechanical properties of the cells (Smits et al., 2010). It not only has roles 
in maintaining the structure of the cellular network, but also in signaling cascades for the 
proper functioning of cells. Fibrous proteins that comprise the ECM are located between 
clusters of cells within all tissue and provide tensile strength, routes for communication, 
and movement of cells within tissues (Kalluri, 2003).  
5 
Basement Membranes 
 Basement membranes are specialized ECM ranging between 50-350 nm in 
thickness and are synthesized by epithelial cells (Kalluri, 2003). They are arranged as a 
sheet-like structure located between cells, cell surfaces, and the interstitium, serving as a 
partition between cell monolayers and the connective tissue space (Yurchenco, 2009). 
Cell monolayers produce and secrete specialized glycoproteins that form the BM on their 
basolateral surfaces (Yurchenco, 2009). Epithelia (including the endothelium) throughout 
the entire body are in direct association with BMs for tissue organization, structural 
support, and regulation in cellular signaling (Kalluri, 2003).  
 The biochemical composition of BMs varies from tissue to tissue and these 
differences are due to tissue-specific expression of protein isoforms, alternative splicing, 
and posttranslational modifications (LeBleu, 2007). Composition of BMs can also be 
relatively dynamic based on the physiologic or pathophysiologic state of tissues (LeBleu 
et al., 2007). Despite the heterogeneous expression of these molecules in tissues, there are 
several proteinaceous components found universally in BMs. 
 Collagen (type IV), laminin, nidogen/entactin, and heparan sulfate proteoglycans 
(perlecan and agrin) comprise the majority of BM molecules and are intricately involved 
in its functions (Yurchenco, 2009). These proteins are extensively coupled to other 
molecules involved in signaling cascades that control cell motility, differentiation, the 
cell cycle, and the expression of other genes and proteins (Yurchenco, 2009).  
Alterations in BM 
 Thickening of the BM, especially in the kidney, is a primary pathophysiological 
feature found in DM patients and is a hallmark of the disease (Bergstrand and Bucht, 
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1959). The hyperglycemic environment present in DM antagonizes the homeostatic 
nature of cells, which activates a biological stress response. One consequence of a 
cellular stress response is the potential alteration of BM composition (Rohrbach and 
Martin, 1982).  
 One of the first diabetic induced alterations of BMs reported was in the kidney 
(Kimmelstiel and Wilson, 1936). Within the renal glomerular mesangium, a network of 
mesangial cells (intercapillary cells) and mesangial matrix provide mechanical support 
for glomerular capillaries (Suzuki et al., 1963). The renal mesangial cells respond to 
injury, by cellular proliferation and increased deposition of matrix molecules, known 
pathologically as Kimmelstiel-Wilson nodules. These are observed in patients with 
diabetic nephropathy (Suzuki et al., 1963). Diabetic nephropathy is characterized by 
increased deposition of ECM proteins in the mesangium as well as BM thickening in the 
glomerulus (Mason and Wahab, 2003).  
 It is widely accepted that increased synthesis of ECM molecules in DM is a result 
of the activation of several pathways, leading to either the increased synthesis of ECM 
proteins and/or the decreased degradation of aged ECM proteins (i.e. decreased ECM 
turnover).   
Hyperglycemia and Reactive Oxygen Species 
 Hyperglycemia has been shown to cause adverse effects on many biochemical 
pathways in vascular tissues and one of these consequences is the excess production of 
reactive oxygen species (ROS) which contributes to increased cellular and extracellular 
oxidative stress (Son, 2007). In general, cells respond to this stress by activating various 
intracellular signaling pathways, and consequently, gene activation (Son, 2007). 
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 Hyperglycemia-induced intracellular signaling has been shown to contribute to 
BM thickening in most tissues through pathways activated by the presence of ROS 
(Sheetz, 2002). Increased levels of ROS in T1D and T2D transpire through a series of 
complex and intertwined molecular pathways.  
 Reactive oxygen species, at moderate levels, are involved in various molecular 
mechanisms and signaling pathways to produce normal cellular responses. The oxidation 
of water, or reduction of molecular oxygen, to give products such as superoxide anion 
(O2-), hydrogen peroxide (H2O2) and hydroxyl radical (+OH) in the mitochondria provide 
biological systems with the majority of ROS (Rains et al., 2011). When ROS are present 
in higher than normal amounts, detrimental consequences to cells, including lipid 
membrane destruction, oxidative damage to DNA, excess cross-linking of proteins, and 
inappropriate activation of stress related signaling pathways could disrupt cell behavior 
(Son, 2007). 
 The mechanisms behind hyperglycemia-induced vascular damage are largely 
driven by the action of ROS. Theories involving four molecular pathways are recognized 
in causing glucose-mediated vascular damage, including, the aldose reductase (polyol 
pathway) theory, activation of protein kinase C (PKC) isoforms, the reactive oxygen 
intermediate theory, and increased intracellular formation of advanced glycation end-
products (AGEs) (Sheetz, 2002).  
 The aldose reductase (polyol pathway) mechanism is activated when intracellular 
glucose concentrations are elevated (Sheetz, 2002). Aldose reductase is an enzyme that 
utilizes nicotinamide adenine dinucleotide phosphate (NADPH) as a reducing agent in 
the conversion of glucose to sorbitol (Madonna, 2011). As a result of the increase of 
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aldose reductase in endothelial cells, sorbitol is oxidized by sorbitol dehydrogenase, 
leading to the production of fructose (Sheetz, 2002). This process occurs with the coupled 
reduction of NAD+ to NADH (Sheetz, 2002). Overall, the increased activity of aldose 
reductase and reduced levels of NADPH causes downstream disturbance of the redox 
balance within the vascular tissues (Sheetz, 2002).  
 Activation of PKC isoforms is also intricately involved in the development of 
diabetic vascular complications. In hyperglycemic environments, PKC is activated and is 
able to alter cellular behavior in various ways. Intracellular hyperglycemic environments 
trigger the activation of a second messenger, diacylglycerol (DAG) (Madonna, 2011). In 
endothelial cells, DAG activates PKC, which triggers intracellular events to alter gene 
expression. Specifically, PKC activation leads to BM thickening by the activation of 
transforming growth factor (TGF) β, collagen, and fibronectin (Madonna, 2011). In 
addition to the activation of DAG, elevated glucose concentrations increase overall 
glycolytic pathway activity and the levels of glyceraldehyde-3-phosphate (GAP) inside 
endothelial cells (Sheetz, 2002). Oxidative phosphorylation of GAP contributes to the 
activation of reactive oxygen intermediates (ROI), initiating an oxidative stress response 
of vascular endothelial cells (Sheetz, 2002).  
 The ROI pathway directly contributes to the oxidative environment of endothelial 
cells and vascular damage through several mechanisms, including oxidative 
phosphorylation of GAP in the previously described PKC signaling pathway. An increase 
in glucose metabolism through the glycolytic pathway and the tricarboxylic acid cycle 
(TCA) increases mitochondrial adenosine triphosphate (ATP) synthesis by oxidative 
phosphorylation (Nishikawa, 2000). Several byproducts of this biochemical process 
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include free radicals, such as the superoxide anion. Increased levels of superoxide anion, 
as previously discussed, generates an oxidative environment and stress on vascular tissue, 
ultimately leading to cellular damage and altered cellular behavior.  
 A fourth mechanism involved in the development of diabetic chronic 
complications is the AGE pathway. Advanced glycation end products are proteins that 
become altered, and irreversibly modified, in the normal course of aging (Sheetz, 2002). 
Increased levels of glucose cause additional covalent modifications and crosslinking of 
proteins and in diabetics this process has been described as a process of accelerated aging 
(Monnier, 1984). Further cellular dysfunction and vascular damage occur by AGEs 
binding receptors to advanced glycation end products (RAGE) (Goh and Cooper, 2008). 
When these transmembrane receptors are activated, additional signaling events are also 
initiated, such as the activation of mitogen-activated protein kinase (MAP) pathway, 
which leads to endothelial cell dysfunction (Schmidt, 2000). 
 A common relationship exists between these four pathways; they are all initiated 
by hyperglycemia and their activation results in an overproduction of superoxide, which 
has been strongly associated with hyperglycemia-induced oxidative stress responses in 
diabetics (Madonna, 2011). Although it remains unclear as to which mechanism is the 
primary source of hyperglycemia-induced production of ROS, it could be the 
combination of these pathways that contribute to vascular complications (Velic et al, 
2013).  
Antioxidant Therapy and Protection against Basement Membrane Thickening 
 The overproduction of free radicals in diabetics is initiated through glucose 
oxidation, nonenzymatic glycation of proteins, and oxidative degradation of glycated 
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proteins (Cai, 2004). One way of neutralizing diabetic oxidative damage, and the 
consequences of oxidative stress (BM thickening), is through the protective properties of 
antioxidants.  
 In this regard, one of the most potent antioxidants referenced in the literature is 
metallothionein (MT). Metallothioneins are a family of proteins known to bind to metals, 
such as zinc (Zn), cadmium (Cd), copper (Cu), and iron (Fe) and cysteine-rich residues in 
cells (Cai, 2004). There are at least ten known isoforms of MT in humans and they are 
further classified into major and minor groups (Thirumoorthy et al., 2011). 
 Metallothionein isoforms have a wide range of protective characteristics, offering 
scavenging against free radicals such as the hydroxyl radical and peroxynitrite, which are 
considered the most active radicals (Cai, 2004). Due to its various protective properties 
and global expression throughout the body, MT isoforms I and II (MTI/II) comprise the 
major group of MTs (Thirumoorthy et al., 2011). As a scavenger of various radicals, MT 
has been shown to be >50 times more powerful than other antioxidants, and thus, MT 
offers promising protective properties against oxidative stress-related damage in cells and 
tissues of diabetic patients (Kumari et al., 1998). 
Antioxidant Therapy 
 Antioxidant therapy has been studied in various animal models to counterbalance 
the overproduction of ROS in diabetic and insulin-resistant mice (Son, 2007). One such 
mouse, the OVE26 (herein referred to as OVE), is a transgenic diabetic mouse that has 
been shown to be a valuable model of human type I DM (Zheng et al., 2008). The OVE 
mouse was developed by introducing a minigene to overexpress calmodulin in the 
pancreatic beta cell (Epstein et al., 1989). Overexpression of calmodulin in the beta cell 
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interrupts the physiological response of these cells to produce and secrete insulin. This 
interruption of insulin production makes the OVE mouse an excellent model to study the 
genetic background of insulin secretion (Epstein et al., 1992). These transgenic mice can 
easily be identified by the phenotypic marker, small eyes. The presence of small eyes is 
caused by the intentional cointegration of the GR19 gene (Liang et al., 2002). The OVE 
mouse is maintained on the Friend virus B-type susceptibility (FVB) background. The 
FVB mice are an inbred mouse strain maintained by the National Institutes of Health 
(NIH) for studying transgenic mice (Taketo et al., 1991).  
 With the establishment of a reliable mouse model that demonstrates common 
characteristics of human DM, it is possible to study the effects of antioxidant therapy. 
Recent studies utilizing these diabetic and transgenic mouse models provide evidence 
that oxidative stress in diabetics can be mitigated. In 2003, Carlson and co-workers 
carried out morphometric analyses of capillary BM thickness in various tissues in 350 
day-old OVE diabetic and normal FVB mice. Interestingly, in addition to the renal 
glomerulus, several other tissues were susceptible to hyperglycemia-induced capillary 
BM thickening. These included skeletal and cardiac muscle, retina and choroid, 
peripheral nerve, lung, and pancreas (Carlson et al., 2003). Not surprisingly, the renal 
glomerulus and ocular retina exhibited the highest susceptibility to BM thickening in 
diabetic mice.  However, the lung and respiratory diaphragm also demonstrated 
significant capillary BM thickening in OVE transgenic diabetic mice.  
 Early work with the OVE mouse and potential antioxidant protection against BM 
thickening was conducted with the development of a transgenic mouse that 
overexpressed MT in myocardial cells (Mt) (Liang et al., 2002). Progeny of the OVE and 
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Mt mice showed significant reduction in myocardial oxidative damage and decreased 
myocardial capillary BM thickening in transgenic diabetic mice. Furthermore, targeted 
overexpression of MT provided antioxidant protection against oxidative stress in cardiac 
myocytes and also protected against diabetic cardiomyopathy (Velic et al., 2013).  
 Metallothionein also has been targeted to other cells in efforts to study its 
protective properties against diabetic nephropathy (DN). The Nmt transgenic mouse 
overexpresses MT in the podocytes of the kidney (Zheng et al., 2008). Moreover, 
progeny of OVE and Nmt mice show significant protection against DN and associated 
glomerular injury (Carlson et al., 2013). Severe albuminuria, glomerular filtration barrier 
damage, and changes in glomerular endothelial and mesangial cell numbers are all 
consequences of DN, and all are reduced by the presence of targeted MT in podocytes 
(Carlson et al., 2013).  
  Overexpression of MT in cardiac myocytes and renal podocytes strongly 
supported the theory of antioxidant therapy in treating oxidative stress related damage to 
these specific tissues. This stimulated a number of investigators to begin efforts toward 
building a transgenic mouse that overexpressed MT in endothelial cells, a cell type 
ubiquitously distributed with the macro- and microvasculature. Accordingly, the 
endothelial cell, appropriately armed with overexpressed MT could show the potential to 
reduce vascular BM thickening globally.  
Jtmt Mice 
 To test the hypothesis of antioxidant protection against diabetes-induced oxidative 
damage in other tissues, the human MTII gene needed to be introduced, universally, into 
endothelial cells. In response to this requisite, a Jtmt transgene was designed and purified 
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by Teiken (2011) to overexpress the human MTII gene, and the purified Jtmt transgene 
was inserted into the developing zygote (into the pronucleus) of FVB mouse embryos 
(Transgenic Mouse Laboratory, Children’s Hospital Research Foundation of Cincinnati). 
 The Jtmt transgene was inserted into the pHHNS plasmid, which contains the 
Tie2 promoter and enhancer for murine endothelial cells. The Tie2 promoter and 
enhancer ensured that the Jtmt gene would be expressed specifically in the endothelium, 
thus creating the Jtmt mouse line (Teiken, 2011).  
 The establishment of a transgenic mouse that overexpresses MT universally in its 
endothelial cells provides a unique vehicle to study antioxidant protection in a wide 
variety of tissues in control and transgenic mouse models. One such tissue, the lung, is a 
particularly appropriate candidate for experimentation. As mentioned earlier, the lung is 
susceptible to hyperglycemia-induced significant BM thickening (Carlson et al., 2003). 
Its similar structural arrangement to the glomerular filtration barrier in the kidney could 
offer insight into the specific cellular mechanisms in BM thickening of each tissue.  
Additionally, as the largest microvascular structure in the body (Shafiee et al., 2013), the 
lung warrants further exploration into potential chronic diabetic pulmonary 
complications, specifically any morphological alterations in the pulmonary alveolar 
basement membrane (PABM). 
Histology of Pulmonary Tissue 
 The respiratory system is divided into two functional parts; the conducting portion 
and the respiratory portion. The conducting portion includes the air passageways from the 
nasal cavity through the level of the terminal bronchioles (nose, pharynx, larynx, trachea, 
bronchi) (Sorokin, 1988). The respiratory portion of the lungs includes the small air 
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spaces from the respiratory bronchioles to the level of the alveoli (respiratory 
bronchioles, alveolar ducts, and alveoli) (Sorokin, 1988). The conducting portion 
functions to bring air in and out of the lungs, whereas the respiratory portion provides an 
outlet for gas exchange.  
 Gas exchange occurs through the thin walled structures, termed pulmonary 
alveoli. More than 300 million alveoli in the human lung provide at least 143 square 
meters of surface area for gas exchange between the inspired air and circulating blood 
(Sorokin, 1988).  
 The alveolar epithelium consists of two cell types, including the Type I and Type 
II alveolar cell. Type I alveolar cells cover a large surface area and are a specialized 
squamous epithelium that on average are less than 0.2 µm thick (Sorokin, 1988). Type I 
alveolar cells are the primary alveolar cells involved in gas exchange in conjunction with 
the endothelium of the alveolar capillaries (Apparao et al., 2010). Type I alveolar cells 
are connected to one another and to Type II alveolar cells by occluding junctions (Bloom 
and Fawcett, 1986).   
 Type II alveolar cells are located in the margins of alveoli and are classified as a 
cuboidal epithelium (Apparao et al., 2010). These secretory cells synthesize and secrete 
pulmonary surfactant, which is a phospholipid that coats the epithelial lining of the 
alveoli (Bloom and Fawcett, 1986). Type II cells are not primarily involved in gas 
exchange, but are structurally related to the organization of the blood-air barrier. Type II 
cells also support host defense in immune responses and act as epithelial progenitors 
(Apparao et al., 2010).  
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 Together Type I and Type II alveolar cells comprise one side of the blood-air 
barrier; the opposite surface is made up of capillary endothelial cells. These capillaries, 
which bring blood to the blood-air barrier of the lung, are surrounded by the interstitium 
of the alveolar septa. Pulmonary epithelium overlie the capillaries at the points where gas 
exchange occurs - and in these areas, the interstitum of the lung is reduced to a thin layer 
of BM (Sorokin, 1988). Thus, oxygen exchange occurs through the blood-air barrier, 
beginning with the endothelium of the capillaries, followed by the BM of alveolar 
capillaries, the thin and sometimes indistinguishable interstitial space, the BM of the 
alveolar epithelium (type I cells), and finally the alveolar epithelium itself (Sorokin, 
1988). The alveolar epithelial BM and endothelial BM of the capillary frequently are 
fused to form the PABM. 
Pulmonary Alveolar Basement Membranes 
 The PABM in the lung is also referred to as the basement membrane zone (BMZ) 
(Evans et al., 2010). The terms basal lamina (BL), basement membrane zone (BMZ), and 
PABM are used interchangeably in the literature. Typically, BM is utilized more often in 
reference to the structure as it appears in light microscopy whereas BMZ and BL refer to 
the same structure at the electron microscopic level or when describing its molecular 
components. The BMZ (herein referred to as the PABM) is comprised of following three 
layers; the lamina lucidia, lamina densa, and lamina reticularis (Evans et al., 2010). 
 On the basolateral surface of the alveolar cell, the lamina lucidia (LL) forms the 
first layer of the PABM. This layer is comprised of collagen (XVII), laminin (5, 6, and 
10), integrins (α6ß4), laminin (1), and collagen (IV) (Evans et al., 2010). The latter two 
proteins are found at the cellular-matrix interface of the LL (Evans et al., 2010). The 
16 
lamina densa is formed primarily by proteins such as entactin/nidogen, proteoglycans 
(perlecans, bamacan, agrin, collagen XVIII), and stored growth factors (FGF-2) (Evans et 
al, 2010). At the matrix interface, the lamina reticularis (LR) is comprised of the 
following molecular components: collagen (I, III, V, VI, and VII), proteoglycans 
(perlecan, bamacan, and collagen XVIII), as well as stored growth factors (FGF-2) 
(Evans et al., 2010).  
 In the lung, the lamina reticularis (LR) is the basal portion of the BM and has also 
been referred to as the reticular BM in the literature (Evans et al, 2010). The LR is 
variable in its distribution throughout the body and is not found in all tissues. However, it 
is present in a number of tissues with multilayered epithelium, including the lung (Evans 
et al., 2010). In pathological states, the LR is often affected, as it serves as a regulator of 
cytokine movement between the alveolar epithelium and the ECM (Evans et al., 2010). 
Interactions involving ECM macromolecules and the LR have the potential to alter 
cellular behavior. Diseased states can interrupt normal signaling cascades by altering 
cellular environments – such as the hyperglycemic environment generated by chronic 
DM. 
Objectives of Current Study 
 Elucidating the molecular and cellular biological pathways contributing to the 
diseased microvasculature in DM is an important area of investigation. As previously 
stated, BM thickening is one of the hallmarks of microvascular complications in DM 
(Carlson et al., 2003). It is the first pathophysiological change in several tissues, 
including the glomerulus of the kidney, myocardial capillaries in the heart, as well as the 
capillaries of the retina (Liang, 2002, Carlson et al., 2003, 2012).  
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 In this regard, the lung is the most highly vascularized organ in the body (Sorokin, 
1988), and since DM is principally a disease of small blood vessels, it seems reasonable 
that the blood-air barrier is highly vulnerable to diabetic microangiopathy, (Shafiee et al., 
2013) including PABM thickening.  
 Accordingly, my working hypothesis is that PABMs exhibit DM-related 
thickening in severely diabetic transgenic mice. Moreover, this structural alteration is 
mitigated by specific endothelial targeted overexpression of MT.   
 If my hypothesis is correct, the results will show that PABM are thicker in 
severely diabetic (OVE) mice than in the healthy control (FVB) and (Jtmt) groups. 
Furthermore, the bi-transgenic (OVEJtmt) group will show a reduced or even eliminated 
PABM thickness increase, strongly suggesting possible antioxidant protection against 
hyperglycemia-driven pulmonary oxidative stress.  
 Results of this study will contribute significant and fundamental data to the 
literature on diabetic BM disease. Furthermore and importantly, baseline ultrastructural 
data on the respiratory filtration barrier and a possible first definition of “diabetic 
pulmonopathy” and potential pulmonoprotection against vascular injury, will offer an 
avenue of new and compelling diabetes research.  
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CHAPTER II 
MATERIALS AND METHODS 
Research Animals 
 Four groups of mice were utilized in this study. Each group was further divided 
into two age cohorts including 60 and 150 day old mice. All groups consisted of at least 
12 (six, 60 day-old and six, 150 day-old) animals. Group I was comprised of healthy 
control Friend virus B-type (FVB) mice (Taketo, 1991).  Group II was age-matched, 
transgenic and severely diabetic mice (OVE) (Epstein et al., 1989, 1992). Group III 
consisted of at least 12 age-matched, transgenic (Jtmt) mice that overexpress 
metallothionein (MT) in endothelial cells (Teiken, 2011). Group IV consisted of at least 
12 age-matched, bi-transgenic and severely diabetic (OVEJtmt) mice. The latter were 
derived from an OVE and Jtmt cross. All transgenic diabetic mice were easily identified 
by a phenotypic marker, which resulted in small eyes, by the intentional co-integration of 
the cataract inducing GR19 gene (Liang et al., 2002).  
 Before sacrifice, mice were weighed and tail tips snipped to procure blood 
samples utilized in hemoglobin A1c (HbA1c) and blood glucose analysis. Micromat II 
(Bio-Rad, Hercules, CA) kits were utilized for HbA1c measurements. The AlphaTRAK 
Blood Glucose Monitoring (test strips and glucose meter) System (Abbott Laboratories, 
Chicago, IL) was employed for blood glucose measurements.  
 All animals were kept in a controlled environment, on a 12-hour light and dark 
cycle, at the Biomedical Resources Facility at the University of North Dakota. Cages
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contained natural pine and/or corncob bedding, which was changed routinely. Purina 
rodent laboratory chow and water were available to the mice at all times and animals 
were maintained according to standards set by the U.S. Department of Agriculture and 
the Institutional Animal Care Committee at the University of North Dakota.  
Genotyping 
 The genetic strain of each mouse was confirmed by real-time polymerase chain 
reaction (RT-PCR), which identified the presence of the MTII transgene. The genetic 
strain identified diabetic and other transgenics from background or control mice. To 
extract DNA, approximately 0.5 cm of tail tips were snipped (with sterilized scissors, 
washed in 70% EtOH between each sample) and immersed in 100µl of Extraction 
Solution (Sigma-Aldrich REDExtract-N-Amp Tissue PCR Kit, Cat. #E7526) in a sterile 
500 µl microcentrifuge tube. Twenty-five microliters of Tissue Preparation Solution was 
added to each microcentrifuge tube and vortexed thoroughly. Tissue digestion was 
carried out by placing the samples in a 55˚C incubator for ten minutes, followed by a 
three-minute incubation in a 95˚C water bath. One hundred microliters of Neutralization 
Solution B was added to the samples followed by vortexing. The neutralized tissue 
extract was then stored at 4˚C until further PCR amplification.  
PCR Amplification 
 To determine the genetic strain of the research animals, PCR amplification was 
performed. According to vendor (Sigma-Aldrich) instructions, DNA was extracted from 
tail tissue using the REDExtract-N-Amp PCR Reaction Mix (Sigma-Aldrich, Cat. 
#R4775) as described above. For each sample, 10 µl of REDExtract-N-Amp PCR 
Reaction Mix, forward and reverse primers (50 nmol/ml), and dH2O were brought to a 
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final volume of 16 µl. Forward and reverse primers (Invitrogen) targeted the human MTII 
gene that was inserted in the Jtmt transgene as described previously (Teiken, 2011). The 
MTII forward primer (AATCGGTTGTGGACTGAGGA) and reverse primer 
(TCACGGTCAGGGTTGTACAT) generated a 536 bp product and control (FVB) strains 
with the forward primer (TCACAATCACCAGGTTTCCAA) and reverse primer 
(CAGCCCAGTCAGAAGTCTAAA) generated a 200 bp product (Teiken, 2011).   
 In a sterile 200 µl microcentrifuge tube, 4 µl of DNA and 16 µl of PCR Reaction 
Mix were combined, vortexed, and were then subjected to PCR thermal cycling. The 
cycling parameters used were as follows: initial denaturation at 94˚C for three minutes 
(one cycle), denaturation at 94˚C for one minute, annealing from 45 to 68˚C for one 
minute, and reverse priming at 72˚C for one-two minutes (all three previously described 
steps repeated for 30 cycles), and finally tissue extraction at 72˚C for one cycle of ten 
minutes. Then samples were loaded directly onto a 1% agarose gel.  
Agarose Gel Electrophoresis 
 Following PCR amplification, 10 µl of amplified DNA was loaded directly into 
1% agarose gels. Gels were prepared by adding 0.5 g of agarose (Fischer) to 50 ml of 
1xTAE buffer (BIO-RAD), heated at power level 10 for 60 seconds in a General Electric 
Turntable Microwave Oven, and gently swirled until all the agarose dissolved. The 
solution was cooled for a minute, after which 3.5 µl of 10 mg/ml ethidium bromide 
(ETBR) was added. The gel was poured into a casting platform and allowed to set for at 
least 20 minutes before samples were added to the wells (formed from the comb inserts 
that were placed into the gel during the cooling and solidifying stage). Finally, 1x TAE 
buffer was poured onto the gel and 10 µl of the samples were added to each well. The 
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samples were run at 80 volts for 40 minutes subjacent to a DNA molecular weight 
marker. Gels were viewed using a High Performance Ultraviolet Transilluminator (UVP 
–Ultraviolet Products). To process and document images, a Carestream GEL Logic 112 
Imaging System was employed.  
Quantification of MT in Pulmonary Tissues 
Tissue Preparation. 
 At 110-170 days of age, FVB, Jtmt, OVE and OVEJtmt, animals were deeply 
anesthetized by injection of sodium pentobarbital (50 mg/ml, 100 mg/kg body weight). 
Upon the absence of limb withdrawal and corneal reflex responses, the abdominal and 
thoracic cavities were quickly incised and the right atrium cut to allow for exsanguination 
and fluid drainage. Pulmonary tissues were harvested, rinsed in saline, blotted dry, and 
weighed. The tissues were then immediately frozen in liquid nitrogen before storage at  
-80°C. Tissues were thawed and minced with a razor blade before placing in 
ultracentrifuge tubes with 2 ml cold (4°C) 0.1M Tris buffer (pH 10.4). For each mouse 
(except the OVE for which only one lung was taken), both lungs were placed in one 
ultracentrifuge tube. Tissues were sonically disrupted using a Sonic Dismembrator 
(Fisher Scientific) until completely in solution. The tissue suspensions were centrifuged 
at 30,000 rpm for 1 hour at 4°C. Supernatants from each sample were collected, vortexed, 
aliquoted into 4, 1.5 ml centrifuge tubes and stored at -80°C. 
Bradford Assay 
 The Bradford assay (Bradford, 1976) was used to quantify the amount of total 
protein in lungs from all mouse genotypes. For each assay, a standard curve was 
generated from a bovine serum albumin (BSA) solution (10 mg/ml; Sigma) diluted in 
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0.01M PBS (Sigma) to a range of 120 µg/ml to 5 µg/ml. PBS was used as a blank. Tissue 
supernatants were diluted in PBS 1:100, 1:200 and 50 µl of each standard and sample 
solution was loaded onto clear polystyrene 96-well plates (Fisher). Bradford reagent 
(Bio-Rad) was diluted 1 part reagent to 4 parts dH20 and 150 µl was added to each well. 
Color development was read on a SPECTRAmax PLUS microplate spectrophotometer 
(Molecular Devices) at a wavelength of 590 nm and the data analyzed by SOFTMax 
software.  
MT Competitive ELISA Assay 
 A competitive ELISA developed by Drs. John Swinscoe and Mandy Meyer 
(Meyer, 2006) was used to quantify the MT in pulmonary tissues from FVB, Jtmt, OVE 
and OVEJtmt mice. For each assay, a Costar EIA/RIA 96-well polystyrene plate (Fisher) 
was coated with 50 ng of MTII protein (rabbit liver; Axxora) in 100 µl of 0.1M Tris  
(pH 10.4) per well and wells that would serve as blanks received only 0.1M Tris. The 
plate was incubated for 6 hrs at room temperature 4°C with slow rotation then washed 
3 times with wash buffer (0.01M Tris, 0.02 NaCl, 0.1% Tween 20, pH 7.2). Standard 
MTII (1 µg; rabbit liver; Axxora) was polymerized in 3% glutaraldehyde, and  
5 µl 0.1M Tris and the tissue sample supernatants were also polymerized in 
3% glutaraldehyde on ice for 60-90 min. Metallothionein readings were maximized at 
90 min. A primary antibody solution was made by diluting the monoclonal mouse anti-
horse MTI/II antibody (Dako, Carpentaria) 130 mg/L; Invitrogen) 1:1000 in primary 
antibody buffer (0.1M Tris, 0.1% Tween 20, pH 10.4) and kept on ice until use. 
 After the 90 min incubation on ice, the standard MTII polymerized solution was 
diluted to 400µl with 0.1M Tris. A standard curve ranging from 0-10 ng of MTII was 
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generated using 16, 12, 8, 4 µl of this standard MTII solution added to 400 µl of the 
primary antibody solution. The polymerized sample supernatants were also added to 
400 µl of the primary antibody solution at room temperature. 
 The plate was washed 3 times in wash buffer. Then 100 µl aliquots of standard or 
sample solution were added to 4 wells. Half of the blank wells received 100 µl of 0.1M 
Tris and the remaining half received 100 µl of primary antibody buffer. The plate was 
incubated at 4°C overnight. 
 The plate was washed in wash buffer 3 times. Then, each well received 100 µl of 
alkaline phosphatase conjugated anti-mouse IgG (1:2500 in 0.01M sodium phosphate, 
0.02M NaCl, 0.1% Tween 20, pH 7.2; Sigma) and the plate was incubated at room 
temperature for 2 hours. The plate was again washed 3 times with wash buffer followed 
by a final wash with dH20. Color was developed by the addition of 4-nitrophenyl 
phosphate disodium salt (10 mg in 10% diethanolamine, pH 10; Sigma). Color was 
allowed to develop for 20-30 minutes. The plate was read on a SPECTRAmax PLUS 
microplate spectrophotometer (Molecular Devices) at a wavelength of 405 nm, and the 
data analyzed by SOFTMax software. 
 Metallothionein values were divided by the volume of tissue sample per well to 
generate a value as ng/µl that was then adjusted to µg/ml. This value was divided by the 
appropriate sample Bradford protein data (µg/ml) to yield the final amount of MT per 
sample as µg/mg pulmonary tissue protein. 
Vascular Perfusion and Tissue Preparation for Microtomy 
 In an effort to prepare excellent samples for immunohistochemical (IHC) or 
morphometric analysis, animals were sacrificed by vascular perfusion through the left 
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ventricle. Prior to perfusion, mice were anesthetized by intraperitoneal (IP) injection of 
sodium pentobarbital (100 mg/kg). Limb and eye reflexes to sensory stimulation were 
checked prior to any incisions, ensuring that the animals were deeply anesthetized. 
Micro-surgical scissors were used to incise the right atrium, to allow fluid drainage and 
exsanguination. Immediately following the incision, a 26G 3/8” hypodermic needle (B-D 
& Co., Rutherford, NJ), attached to plastic medical grade 0.020 inch tubing was inserted 
into the left ventricle for infusion of 50 ml warm isotonic (0.9M) saline and additional 
perfusates to clear the vascular bed. Flow rates for saline and fixatives were set at 
approximately 6 ml/min. At the time of perfusion, several organs including the lung, 
heart, kidneys, and retinas were harvested to prepare an adequate diversity of tissue 
sample. Perfusion was deemed adequate when eyes, lips, and tail of the mouse became 
pale and limbs were rigid. 
Perfusion Using Zamboni’s Fixative 
 Tissue samples prepared for IHC analysis were perfused and fixed with 
Zamboni’s (Zamboni and Stefanini, 1968) fixative. This fluid was prepared by dissolving 
4 g of paraformaldehyde in 25 ml of distilled water heated to 50˚C. Twenty ml of 0.5M 
sodium phosphate buffer and 16.5 ml picric acid were added to the solution, which was 
then stirred, cooled to room temperature, and filtered. The solution was brought to a final 
pH of 7.4 by drop wise addition of 1N sodium hydroxide (NaOH) or 1N hydrochloric 
acid (HCl). The fixative was brought to a total volume 100 ml by adding 38.5 mL of 
dH2O.  
 Prior to perfusion, animals were anesthetized as described above. Perfusion was 
initiated with 50 mls of filtered prefixative (0.9% NaCl, 0.1% NaNO2, and 100 units of 
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heparin in dH2O) administered at a rate of 6-7 ml/min, followed by 100 mls of full 
strength Zamboni’s fixative. Immediately following perfusion, pulmonary tissue was 
surgically removed and immersed in cold Zamboni’s fixative for three hours. Tissues 
were stored in 25% sucrose buffer (sucrose, glycerol, 0.5M phosphate buffer, 1% sodium 
azide in dH2O) at 4˚C overnight before embedding in paraffin.    
Perfusion Using PIPES Fixative 
 All animals were adequately anesthetized and perfusion was initiated as 
previously described. For preparation of tissue samples for TEM observation and TEM 
morphometry, glutaraldehyde-based PIPES fixative (Bauer and Stacey, 1977) was 
employed. PIPES fixative was freshly prepared for each perfusion procedure. The 
fixative consisted of PIPES buffer (PIPES {Piperazine-N,N’-bis[2-ethanesulfonic acid]} 
(Sigma: P8203-250G), 1N NaOH, distilled water), and 20% dextran (Sigma: D4626), 
10% paraformaldehyde, and TEM grade glutaraldehyde 10% (Tousimis, #1060A). 
Following observation of clear fluid drainage from the right atrium, 20 ml of warm 
fixative and then 40 ml of cold fixative was administered. Organs harvested from mice 
were immediately immersed in vials of cold PIPES fixative for approximately 
30 minutes.  
 Tissues were minced to 1 𝑚𝑚3 blocks and placed in cold fixative for three hours 
and then washed in PIPES buffer with 2% sucrose for 30 minutes, at room temperature. 
Blocks were then immersed in a 1:1 solution of 2% osmium (OsO4) (Stevens 
Metallurgical Corp., NY, NY), 3% potassium ferricyanide (K3Fe(CN)6  and distilled 
water in PIPES buffer with one part PIPES buffer, 6% (sodium iodate) NaIO3 (Fisher Cat 
# 5322-100 P.259C) and 4% sucrose overnight. Following overnight treatment with 
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buffered OsO4, tissue samples were dehydrated in an ascending series of alcohols as 
follows: two five-minute treatments with 15% ethanol (EtOH), two ten-minute treatments 
with 30% EtOH, two 15 minute treatments with 50% and 70% EtOH, three 20-minute 
treatments with absolute EtOH, and finally, two one-hour washes in absolute EtOH. 
 Following dehydration, tissues were rinsed briefly in propylene oxide (1,2 epoxy 
propane), followed by two additional 15-minute propylene oxide washes, and a 1:1 
solution of epoxy resin and propylene oxide. The epoxy resin consisted of Araldite 502 – 
Modified Bisphenol A Epoxy (EMS, Cat. #10900), EMbed-812 (Epon-812 Substitute) 
(EMS, Cat. #14900), Dodecenyl Succinic Anhydride (DDSA) (EMS, Cat. #13710), and 
2,4,6,-{Tri(Dimethylaminoethylphenol} (DMP-30) (EMS, Cat. #13600).  
 The final step in tissue preparation included an overnight incubation in a 3:1 
solution of epoxy resin and propylene oxide before an 18-hour incubation in full strength 
epoxy resin. All tissues were then embedded in fresh epoxy resin and incubated at 65˚C 
for at least 72 hours.   
Paraffin Embedding 
 Tissues perfused with Zamboni’s fixative were embedded in paraffin for 
immunohistochemical analysis by light microscopy. Tissue dehydration was carried out 
in a series of graded alcohols, beginning with 50% EtOH for 30 minutes, followed by 
70%, 80%, 95%, and 100% EtOH for 30 minutes each (repeated twice). Tissues were 
then immersed in two washes of CitroSolv (Fisher) for 20 and 30 minutes followed by 
60 minutes in a 1:1 Paraplast (Fisher):CitroSolv solution, and two 60-minute rounds in 
full-strength Paraplast in a vacuum oven at 60˚C. Pulmonary tissue was embedded in 
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plastic molds using a cooling table on a paraffin embedding apparatus. Tissues were 
maintained at -20˚C for at least 24 hours prior to sectioning.  
Immunohistochemistry 
 For IHC analysis, paraffin blocks were trimmed with tEM single-edge stainless 
razor blades (Tousimis #7250) to form a pyramidal shape face. Blocks were then placed 
in a Leica RM2125 microtome and sections of tissue were cut at approximately 5-7 µm 
with a biological grade steel knife. Ribbons of tissue serial sections were placed in a 
water bath (40˚C TissuePrep). Sections were collected on glass slides coated with poly  
L-lysine (Histology Control Systems, Glen Head, NY). Slides were stored at 4˚C until 
they were used for IHC procedures.  
 A Tissue-Tek® Slide Staining Set (Electron Microscopy Services) was used to 
immerse slides in CitroSolv for paraffin removal. This was repeated three times for five 
minutes per immersion, followed by subsequent rehydration in a series of graded alcohols 
(70%, 95%, and 100% EtOH three times for 5 minutes). Slides were then rinsed for five 
minutes in gently running cold tap water. A liquid blocker PAP-pen (EMS, Cat. #71310) 
was used to encircle the tissue on slides after the five-minute water bath, and the slides 
were placed in a humidifying chamber with 3% hydrogen peroxide (H2O2) for one hour. 
Next, slides were subjected to 10% normal rabbit serum for 20 minutes and then mouse-
to-mouse blocking reagent (Scytek) for 30 minutes. After a one-hour incubation in 1% 
Blocking Reagent (Invitrogen) [10mg/ml in 0.01M PBS (Sigma)], slides incubated for 
one hour in primary antibody, at a 1:100 dilution (in 1% Blocking Reagent). The MT 
primary antibody (mouse anti-horse MTI/II, Dako) was administered to positive controls 
(renal tissues from animals overexpressing endothelial MT (Teiken, 2011)), while the 
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same tissue treated with 1% Blocking Reagent only served as negative controls. Slides 
were then rinsed three times in 0.01M PBS, then treated one hour with biotinylated rabbit 
anti-mouse IgG (Invitrogen) at a 1:200 dilution in 1% Blocking Reagent.  
 Following three rinses in 0.01M PBS, slides were treated in a humidifying 
chamber with Horse Radish Peroxidase (HRP) conjugated streptavidin (Invitrogen) at a 
dilution of 1:500 in 1% Blocking Reagent. All slides were then exposed to a 1:10 solution 
of 3,3’-Diaminobenzidine (DAB) in 0.01M PBS and a 1:1000 solution of 30% H2O2. A 
final rinse in cold tap water preceded a nuclear counter stain with 0.5% methyl green on 
low heat. Slides were allowed to dry overnight prior to the addition of Permount attached 
cover slips and observed by bright field light microscopy.  
Microtomy 
 Epoxy blocks containing pulmonary tissue were trimmed to form a trapezoid face 
with a 1 mm base with tEM single-edge stainless razor blades. An MTX ultramicrotome 
equipped with a gem grade diamond knife (DiATOME) and an MTX ultramicrotome was 
utilized for making thick and thin tissue sections. First, thick sections (250 nm) of tissue 
were made and examined by light microscopy to identify tissue location and position. 
Thick tissue sections were collected on a drop of dH2O on a glass slide and were dried on 
low heat. Slides were stained with 1% toluidine blue in 1% sodium borate, and following 
the addition of cover slips were examined by bright field (Olympus BH-2) microscopy. 
 When ultramicrotomy was deemed appropriate, thin sections (70 nm) were cut 
and ribbons of tissue sections were collected in a dH2O metal trough. A cotton swab 
dipped in chloroform was passed over the sections to eliminate wrinkles within the tissue. 
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Ribbons of tissue, with an optimal interference color of silver, were collected on 300 μm 
mesh naked copper grids.  
Light microscopy 
 Glass slides stained with 1% toluidine blue or immunohistochemically, as 
described above, were viewed on a brightfield Olympus BHS (BH-2) light microscope. 
An Olympus 63x and 100x oil immersion objective lenses were used to view any 
pathological features of pulmonary tissue.  Images were captured using a SPOT Idea 
Digital Microscope Camera and SPOT imaging software version 4.6 (Diagnostic 
Instruments, Inc.).  
Staining procedure for TEM grids 
 Tissue samples for TEM on copper grids were stained with 2% uranyl acetate and 
lead citrate (Venable and Coggeshall, 1965). Uranyl acetate was prepared by dissolving 
0.4 grams of uranyl acetate in 10 ml of distilled water. A one to one solution of 4% 
uranyl acetate was made with absolute EtOH, followed by filtration through a 0.2 μm 
filter (Thermo Scientific, Cat. No. 190-2520). Grids were stained for five minutes on 
silicone mats (PELCO®, #10521) in petri dishes covered with aluminum foil for 
protection from photon exposure. Grids were rinsed with distilled water before staining 
with lead citrate. Initially, 0.6 grams of lead citrate was mixed in 20 mls of boiled water, 
followed by the drop-wise addition of 10N sodium hydroxide to clear the solution 
(Venable and Coggeshall, 1965). The lead solution was then centrifuged for 15 minutes. 
The staining procedure was repeated, leaving grids on the silicone mats for 5 minutes in 
covered petri dishes lined with NaOH pellets to protect grids from CO2 exposure. Grids 
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were then rinsed thoroughly in distilled water and allowed to dry for a minimum of 
24 hours in grid storage boxes.  
Transmission Electron Microscopy 
 Thin sections of pulmonary tissues were photographed in a Hitachi 7500 TEM at 
an initial magnification of x30,000. Ten micrographs were obtained from each tissue 
block (two blocks per mouse), totaling at least 240 micrographs for each mouse 
genotype. Micrographic films (Kodak 4489) were developed by conventional methods, 
scanned (Epson Perfection V750 Pro scanner), and printed (HP LaserJet P2015 printer) 
on plain 8.5”x11” paper. Prior to printing, each micrograph was magnified by exactly 
2.8X (Adobe Photoshop) to guarantee a final magnification of precisely x84,000. This 
relatively high magnification was chosen to ensure accurate marking of PABMs on 
finished prints.  
 Random perpendicular widths of the PABM were marked utilizing a transparent 
grid overlay (three cm squares) placed onto each micrograph. This established true 
randomization in marking PABMs. Only points of PABM that intersected the grid were 
marked for measurement. Accordingly, all points along the PABM were equally likely to 
be selected and operator choice was not an option. 
Unbiased TEM Morphometry 
 As mentioned above, operator bias in PABM measurement was eliminated and 
measurement consistency was maintained with the use of a transparent grid overlay. In 
pulmonary tissue, the inner plasma membrane of the endothelial cell (of the blood-air 
barrier) was used as a reference for the starting point of measurements. Where alveolar 
cells crossed the superimposed grid, a mark is made at the point of PABM intersection.   
31 
 By the orthogonal intercept method (Jensen et al., 1979), a diagonal line was 
drawn across the PABM from the beginning reference point on the endothelial cell to the 
plasma membrane of the perpendicularly located alveolar cell. Using a digitizing tablet 
and specialized software (Bioquant, R and M Biometrics, Inc.), the length of the 
perpendicular lines (orthogonal intercepts) were measured and distributed into one of 
nine classes of thickness (Hirose et al., 1982). The harmonic mean apparent thickness 
(Dische, 1992) of the measurements was then calculated and multiplied by 8/3π (Jensen 
et al., 1979) to eliminate an expected right-sided skew of the numerical distribution and 
to give the true PABM width (Gundersen and Osterby, 1973). 
 At least ten images were taken of each block, which allowed for the analysis of at 
least 120 micrographs per mouse. On average, one micrograph provided approximately 
ten PABM measurements. Taken together, this resulted in > 485 micrographs measured 
in the 60 day-old group, and approximately 4,000 PABM measurements available to 
calculate harmonic means (Table 3). The 150 day-old cohort showed similar averages for 
blocks per mouse, micrographs obtained per block, and average number of PABM 
measurements per micrograph. Accordingly, the total number of PABM measurements 
used to calculate the harmonic means in the 150 day-old group was ~4,400. 
Statistics 
 Distributions of “true” PABM thickness [as derived from orthogonal intercepts on 
sets of at least 20 micrographs for each animal type (FVB, Jtmt, OVE and OVEJtmt)] 
were statistically compared using the nonparametric Wilcoxon-Mann-Whitney rank-sum 
test as previously described (Carlson et al., 2003, 2004).  Significance value for all tests 
was set at P≤0.05.
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CHAPTER III 
RESULTS 
General Condition of Animals 
 In general, 60 day-old FVB and Jtmt mice are physically active, exhibit sleek and 
shiny coats, and are approximately of equal size (Figure 1A). The diabetic animals (OVE 
and OVEJtmt mice) also demonstrate active behaviors at 60 days.  However, their coats 
are noticeably less sleek and appear patchy. All diabetics, including OVE and OVEJtmt 
mice are recognizable by their small eyes (Figure 1B), but otherwise cannot be 
distinguished from each other. No other obvious physical characteristics are different 
among the four genotypes.  
 Likewise, at 150 days of age, FVB and Jtmt mice are physically indistinguishable 
and maintain healthy body weights, sleek coats, and active physical dispositions. 
However, their diabetic counterparts are easily identifiable as they not only exhibit small 
eyes, but their coats are generally patchier and dull. Diabetic mice also tend to be 
somewhat lethargic and weigh less than Jtmt mice (Table 2). Glycated hemoglobin levels 
in OVE and OVEJtmt mice are consistently higher than FVB and Jtmt mice (Table 2). 
Fasting blood glucose measurements are consistent with HbA1c data and also are 
decidedly higher in the diabetics than FVB and Jtmt mice (Table 2). 
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Pulmonary Morphology 
Light Microscopy 
 Light microscopic images of toluidine blue stained thick sections of pulmonary 
tissue from 150 day-old mice (Figure 2A) show typical textbook features of respiratory 
tissue. By this technique the terminal portion of the respiratory system can be visualized. 
This region contains terminal bronchioles, respiratory bronchioles, alveolar ducts, 
alveolar sacs, and individual alveoli. However, only alveolar ducts, alveolar sacs, and 
alveoli are seen by conventional toluidine blue staining (Figure 2A). Alveolar ducts are 
surrounded by pockets of alveolar sacs that terminate in individual alveoli. The latter are 
separated from each another by alveolar septa. Small veins also can be seen in cross 
section, with occasional intravascular erythrocytes. Individual components of alveolar 
walls cannot be identified at the LM level, but the thin respiratory filtration barrier can 
still be appreciated. Type I alveolar cells are the most common cell type contributing to 
the large surface area for gaseous exchange. This extensive layer is manifested 
morphologically as an external attenuated cytoplasm of the respiratory filtration barrier. 
Transmission Electron Microscopy 
 Components of the respiratory tissue in 150 day-old FVB mice that are not 
identifiable at the LM level, are clearly resolved by TEM. The small rectangular area 
drawn in the large original LM image (Figure 2A) illustrates the approximate size of the 
area shown in the TEM inset at the bottom of the figure (Figure 2B). The inset TEM 
image (Figure 2B) illustrates structures that could be expected to be found included in the 
small rectangle in Figure 2A at an original magnification of approximately 100x. Type II 
alveolar cells are located in the inter-alveolar septa where they offer structural support to 
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surrounding alveolar and capillary networks. Circulating lymphocytes and erythrocytes 
occasionally occupy capillary spaces. Structural components of the respiratory filtration 
barrier, such as the meshwork of elastin and collagen that lies within the extracellular 
space, can usually be found in the alveolar septa. Intracellular structures in type II 
alveolar cells (e.g. nuclei and lysosomes) can be identified by low magnification TEM 
(Figure 2B).  
 Increasing the TEM magnification to 16,000 diameters offers a sharper resolution 
and the PABM appears as an electron dense structure surrounding alveoli, though the 
PABM still is not easily measured for data collection and analysis (Figure 3). Bundles of 
elastin are also more apparent at this magnification. They are often located in the 
structural matrix between A1 and A2 cells, (located in the upper right corner of the 
Figure 3). Endothelial cells line the capillary space and are present on the intravascular 
side of the PABM. Alveolar type I cells line the air space on the opposite side of the 
PABM. Other interesting features include endothelial flaps that are identifiable where 
endothelial cells come together to form tight junctions. 
 Increasing to an even higher magnification of 60,000 diameters (Figure 4) 
demonstrates individual components of the respiratory filtration barrier and allows for 
consistent, accurate, and unbiased PABM measurement and data collection. The 
cytoplasm of the thin endothelial cells line the internal side of the blood-air barrier, and is 
separated from the alveolar epithelium by the PABM.  Endothelial cells are orientated 
toward the left and right external side of the filtration barriers in Figure 4. Type I alveolar 
cells line the air space and are located toward the middle of the micrograph. Between the 
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two cell layers, the PABM runs the length of the micrograph in a superior to inferior 
direction. 
 At the LM level, individual PABMs are not recognizable or measureable. 
Accordingly, in the current study TEM is required to clearly and reliably identify the 
limits of the PABM of the lung. Four groups of mice are utilized to study the PABM, and 
at 60 days of age, and a magnification of 60,000 diameters, variations in PABM thickness 
between genotypes can be appreciated (Figure 5). The PABM of each mouse genotype is 
illustrated by the opposing arrowheads and are ordered as follows; 60 day-old FVB 
PABM (Figure 5A), 60 day-old Jtmt PABM (Figure 5B), 60 day-old OVE PABM 
(Figure 5C), and 60 day-old OVEJtmt PABM (Figure 5D). In Figures 5 A-D, endothelial 
cells are much thinner than type I alveolar cells. This structural characteristic is an 
excellent aid in discriminating between capillary and alveolar components of the 
respiratory filtration barrier. Endothelial cells in each image in Figure 5 are positioned 
toward the superior portion of the micrograph (as indicated in Figure 5D), and the A1 
cells face the inferior portion of the PABMs in Figures 5 A-D. Generally, the capillary 
endothelium lines the concave side of the PABM and type I alveolar cells form its convex 
border.  
 Micrographs of 150 day-old lung tissue show morphological features remarkably 
similar to those obtained at 60 days of age. By visual inspection, the PABM of 150 day-
old FVB mice (Figure 6A) appears considerably thinner than PABMs from Jtmt 
(Figure 6B), OVE (Figure 6C), and OVEJtmt (Figure 6D). Significantly, the 150 day-old 
OVE (Figure 6C) PABM is appreciably thicker than the other age-matched PABMs in 
Figure 6. Similar to observations in the 60 day-old lungs, the endothelial cells are much 
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thinner compared to their type I alveolar cell counterparts, and are orientated in the same 
manner as previously described. 
Pulmonary Alveolar Basement Membrane (PABM) Morphometry 
 Interestingly, PABM measurements obtained in the 60-day group generate 
harmonic means within a very small range (Figure 7) shown as the PABM thickness of 
FVB, Jtmt, and OVE mice all approach 50.0 nm. These data affirm our preliminary visual 
observations of these PABMs, which suggest that they are relatively similar in width. 
Statistical significance value is set at P < 0.05. 
 As anticipated, the greater PABM thickness differences noted by preliminary 
visual observation in 150 day-old mice relative to 60 day-old animals is confirmed by 
orthogonal intercept analysis (Figure 8). Not surprisingly, the OVE genotype exhibited 
the thickest PABM measurements. Moreover, the largest margin of difference between 
any two genotypes was the interval between 150 day-old OVE and OVEJtmt mice. The 
nonparametric Wilcoxon-Mann-Whitney rank-sum test indicated statistical significance 
between PABM thicknesses in the FVB and OVE groups (P = 0.020), Jtmt and OVEJtmt 
groups P = 0.0095), and OVE and OVEJtmt groups (P = 0.012) at 150 days of age. 
Statistical significance value is set at P < 0.05. 
 When both age groups are analyzed together, statistically significant differences 
were observed between the 60 day-old OVE and 150 day-old OVE genotypes (Figure 9). 
However, this significant difference is completely eliminated when OVEJtmt mice in the 
two age groups are compared. Interestingly, FVB mice show no significant changes in 
PABM width with age. (Figure 9). Significantly, 150 day-old Jtmt PABMs average 
~52.76 nm, a 5.4% thickness increase over 60 day-old mice of the same group. At 150 
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days, PABMs in OVEJtmt mice are increased by 6.1% over 60 day-old mice (~47.75 nm 
compared to ~44.97 nm) while OVE mice show the largest age-related PABM width 
increase, an average of ~51.49 nm compared to ~58.42 nm, or approximately 18.3%. 
 When compared to age matched controls, 150 day-old mice exhibit diabetes-
induced PABM thickening in the OVE group (~58.42 nm) but more importantly; a 
significantly (P = 0.012) reduced PABM width is demonstrated in OVEJtmt mice 
(~47.75 nm). Also, FVB mice show levels of thickening similar to the Jtmt group with 
averages of ~48.71 nm and ~52.76 nm, respectively (Figure 9A). 
Analysis of MTI/II Expression 
Immunohistochemical Analysis of MTI/II in 150-Day Lung Tissue.  
 To identify the expression of MT I/II in endothelial cells of the lung, IHC analysis 
was utilized. Positive controls from Jtmt mice were obtained from the kidney (Figure 
10B) and were treated with primary antibody as previously described. Negative controls 
were derived from the same tissue. However, these samples were not exposed to primary 
antibody and received blocking reagent in its place. As expected, the positive controls 
showed light brown staining of the MT I/II antibody in the endothelium. Negative 
controls indicated no MT I/II staining. 
 Positive staining for MT I/II in the endothelium of the lung was also visible 
(Figure 10D and F). Lungs from Jtmt and OVEJtmt showed positive expression of MT 
I/II as indicated by light brown staining around the endothelium of small veins. 
Immunohistochemical staining indicated that MT I/II was expressed in the pulmonary 
vasculature of the transgenic mouse lines, which suggested quantification of MT I/II 
could be executed.  
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Competitive ELISA of MTI/II in 150-Day Lung Tissue  
 At 150 days of age, lungs from an FVB, OVE, Jtmt, and OVEJtmt mouse were 
obtained to quantify MT I/II present in pulmonary tissue by the competitive ELISA 
method. Metallothionein levels were expressed per total μg of protein in each tissue 
sample. Levels of MT I/II in each genotype were as follows: FVB (0.23 μg/mg), OVE 
(0.22 μg/mg), Jtmt (0.45 μg/mg), and OVEJtmt (0.33 μg/mg). Importantly, the Jtmt lung 
measured MT I/II two times the amount found in the FVB control. The OVEJtmt 
pulmonary tissue also measured higher MT I/II protein levels than the controls, but were 
not as elevated to the levels of the Jtmt pulmonary tissue. Data obtained from this method 
was remarkably consistent with the staining patterns found in IHC analyses of the same 
tissue.   
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CHAPTER IV 
DISCUSSION 
 Basement membrane thickening was identified in diabetic patients more than 
50 years ago and has long been considered the morphological hallmark of the disease 
(Bergstrand and Bucht, 1959). Early studies on the effects of DM on BMs indicated 
changes in protein composition in diabetic mice compared to healthy controls (Rohrbach 
and Martin, 1982). Laminin and collagen IV synthesis was induced in diabetic mice, 
although the synthesis of proteoglycans was inhibited in these same animals. Treating 
diabetic mice with insulin returned the synthesis of proteoglycans to normal levels over 
time, suggesting that the lack of heparan sulfate proteoglycan stimulated the 
overproduction of laminin and collagen IV in an effort by cells to compensate for the loss 
of proteoglycan synthesis leading to decreased BM turnover and increased BM width 
(Rohrbach and Martin, 1982).  
 More recent studies on diabetic animals have suggested that although expression 
of some ECM proteins is increased, it is not clear that such synthesis is the result of 
compensatory hypertrophy.  In fact, it is apparent that BM thickening in most diabetic 
models is due largely to the lack of breakdown and turnover of matricellular molecules, 
and not an overexpression of various ECM proteins (Tsillibary, 2003).  
 Although the mechanisms leading to increased BM width have been elusive, as 
pointed out in the Introduction, considerable progress has been made in unpacking the 
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potential regulatory pathways leading to decreased ECM turnover in DM. Recently, an 
interesting unifying hypothesis was offered (Brownlee, 2001) that suggested that in the 
hyperglycemic state, oxidative stress, mainly derived from mitochondrial activity, 
generated high levels of free radicals (small charged oxygen ions), capable of 
considerable tissue damage. Moreover, numerous studies aimed at reducing the mass of 
free radicals have reported remarkable mitigation of a variety of chronic diabetic 
complications in the kidney and heart, (Carlson et al., 2013; Velic et al., 2013).  
 A review of the literature shows that attempts to link DM and pulmonary structure 
and function have been sparse, inconsistent and contradictory. Basement membrane 
thickening in the lung has been reported in several pulmonary pathologies, but has not 
been correlated directly with DM. Typically BM thickening has been identified in other 
diseases, including asthma, chronic obstructive pulmonary disease, tuberculosis, and lung 
cancer (Watanabe, 1997). However, BM thickening in these studies focused primarily on 
bronchiolar BMs and cannot be compared to PABMs, where the majority of gas 
exchange occurs. 
 It must also be pointed out that diabetes-related research has not focused on 
pulmonary tissues because of the high probability that extant clinical complications may 
be masked by more serious manifestations, including kidney failure. Nevertheless, a few 
studies (Vracko, ’79; Kida et al., ’83; Fuso et al.,’96) have given some attention to the 
diabetic lung and suggest that pulmonary tissues may be somewhat affected by the 
disease.  
 In 1979, Vracko utilized post mortem tissue from human diabetics in a TEM 
analysis of alveolar and pulmonary capillary basement membrane thickening of diabetic 
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patients. Unfortunately, the PABM thickening data was not measured at the points where 
alveolar and endothelial BMs fuse to form the PABM. Additionally, the data was not 
correlated with the duration of the disease, or with the age of the patient.  
 A later study (Kida et al., 1983) centered on the volume proportion of the alveolar 
wall, reported a 24% increase in streptozotocin-induced diabetic rats, though the data was 
not statistically significant. On the other hand, these investigators demonstrated a 
significant increase in the number of alveoli (per unit volume) in diabetic rats compared 
to normal controls, as well as an increase in surface to volume ratio (Kida et al., 1983). 
However, a direct correlation between DM and these changes could not be shown 
because the effect of insulin treatment was not studied. Accordingly, potential side effects 
of streptozotocin (a nephrotoxin and possible pulmonotoxin) on the lung could not be 
ignored (Ofulue et al., 1988).  
 Furthermore, it has been speculated that diabetic patients, specifically Type I 
diabetics, have a decreased capillary blood volume and carbon monoxide diffusing 
capacity (Fuso et al., 1996). However, published results on this subject are conflicting 
(Fuso et al., 1996). Contradictory data reported in studies measuring diffusing capacity 
and capillary blood volume, were likely due to differences in the manner in which 
patients were tested (e.g. supine vs. sitting). It is well known that variations in testing 
parameters (including body position in pulmonary function tests) alters the functional 
recruitment of superior pulmonary lobe capillaries as well as the specificity and 
sensitivity of these tests (Fuso et al., 1996). 
 Accurate histological descriptions of pulmonary alveoli demonstrate a three-
layered structure including an external layer of alveolar cells, and an internal layer of 
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endothelial cells both of which lie immediately subjacent to the central PABM (Cross and 
Mercer, 1993). In vertebrate animals, this tripartite morphological pattern is repeated only 
in the urinary filtration barrier of the kidney where the GBM is lined internally by 
glomerular podocytes and externally by fenestrated endothelium. To be complete, the 
choroid plexuses located in the ventricles of the brain exhibit some structural similarities 
but only in the lung and kidney are two BMs truly fused to form a single PABM or GBM 
that serves as a passive (though size-selective and charge-selective) filter. 
 Despite patient compliance and rigid insulin injection schedules, increased GBM 
width is widely recognized as a diagnostic feature of both Type I and Type II DM. 
Interestingly, its pulmonary counterpart is rarely mentioned and has received little 
morphometric investigatory activity.  
 Accordingly, the current investigation was designed to follow up on a single 
preliminary study by Carlson et al., (2003) that showed that although not all varieties of 
BMs are subject to significant diabetic thickening, the GBM and several other types, 
including PABM, were remarkably vulnerable to thickening in severely diabetic OVE 
mice. 
 The present study was patterned after a remarkable investigation (Zheng et al., 
2008) that reported severely diabetic (OVE) mice were protected against albuminuria and 
several other diabetic parameters by crossing them with transgenic mice with specifically 
targeted antioxidants (MT), particularly powerful scavengers of free radicals injurious 
ions widely suspected to mediate tissue damage in most chronic complications of DM. In 
fact, the ROS scavenging activity of MT has been shown to be greater than 50 times 
more effective than GSH (Sato and Bremner, 1993).  
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 These studies motivated co-workers in the Carlson laboratory (University of 
North Dakota School of Medicine and Health Sciences) to investigate the efficacy of MT 
in ameliorating diabetic complications, including BM thickening, in the heart (Velic et 
al., 2013), kidney (Carlson et al., 2013), and pancreas utilizing unbiased TEM 
morphometry (Chen et al., 2001). The results of these studies were universally positive 
and in each case, breeding OVE diabetic animals to specific MT overexpressors (Nmt, 
glomerular podocytes; MT, cardiomyocytes), BMs of subjacent microvascular cells in the 
diabetic animals were significantly protected from reaching the widths of untreated 
diabetic mice. 
 These results concerted efforts to generate a strain of mice in which the effect of 
MT overexpression could be evaluated more globally. Therefore in 2011, Teiken utilized 
the Tie2 promoter and the MT II isoform to generate a plasmid that could be used to 
develop a transgenic mouse that overexpressed MT specifically and ubiquitously in 
endothelial cells. 
 Importantly, immunohistochemical analysis confirmed that MT is widely 
expressed in Jtmt endothelial cells and although the very small and delicate nature of the 
respiratory filtration barrier (particularly the < 2 µm thick pulmonary endothelium) 
reduced the visualization quality of MT in this layer, preliminary results from the more 
sensitive competitive ELISA technique is encouraging. This method suggested that 
pulmonary endothelial cells from Jtmt mice carry at least a 2 fold increase in MT 
compared to FVB controls. These data strongly supported our claim that the human MT 
I/II transgene was successfully overexpressed in the endothelial cells of transgenic mice 
(Teiken, 2011).  
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 The new mouse (called Jtmt) was successfully developed and is a remarkably 
effective model for mitigating BM thickening by crossing it with diabetic mice. In this 
regard it has been shown to completely eliminate hyperglycemia-driven GBM and 
myocardial capillary BM thickening, and it was the only known experimental protocol to 
fully mitigate diabetic BM thickening. 
 In light of preliminary studies showing that PABM was one of only a few BMs 
that are significantly widened in the diabetic OVE mouse (Carlson et al., 2003), the 
current Jtmt study utilized unbiased TEM morphometry to test my working hypothesis. 
The overall paradigm was designed to determine whether diabetes-induced oxidative 
stress might be a major factor in any possible PABM increased width, and secondly to 
determine the effect of MT overexpression in endothelial cells on PABM thickness.  
 The severely diabetic OVE mouse (Epstein et al., 1989) was chosen for the 
experimental model because early studies using this model of type I DM showed 
significant BM thickening in a wide variety of tissues including kidney (glomerulus), 
heart (myocardial capillaries), retina (choroid), lung, and peripheral nerves (Carlson et 
al., 2003, 2004, 2013).  Although the lungs have not previously been implicated in 
chronic complications of DM, its highly vascularized parenchyma and potential for 
extensive oxidative damage warranted further study into potential hyperglycemia-driven 
PABM thickening.  
 To our knowledge, the current study was the first to report carefully applied 
morphometric methods to show PABM thickening in transgenic diabetic animals, and it 
was clearly the first to show that overexpression of MT in endothelial cells mitigated 
hyperglycemia-induced PABM thickening. Using a transgenic mouse line, we were able 
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to study DM in a remarkably long-living animal model (Carlson et al., 2013) that exhibits 
a plethora of pathophysiological features similar to those found in humans (Teiken et al., 
2011). In addition, this model avoided any adverse effects of inducing diabetes in animals 
by the use of semi-toxic pharmaceutical drugs (e.g. streptozotcin) that may have serious 
side effects.  
 Our studies indicated that at 60 days of age, no significant differences were 
evident between PABM thickness in FVB, Jtmt and OVE, while OVEJtmt showed mildly 
thinner PABMs. This was undoubtedly due to the youth and immaturity of the mice when 
diabetes-induced complications were not manifested. Not surprisingly, light microscopy 
and TEM morphometric analysis showed no fundamental changes between the diabetic 
genotypes versus healthy controls. Additionally, a thorough investigation of BM 
thickness increases in other tissues at 60 days of age would be necessary to determine the 
approximate age of onset of vascular complications in diabetic mice.   On the contrary, at 150 days changes in PABM thickness between diabetic and 
healthy control mice were measurable and significant. Interestingly, the OVEJtmt 
bitransgenic mice showed a significantly reduced PABM thickening compared to the 
OVE and FVB lines. These data strongly supported the existing considerable evidence 
that ROS may be a primary cause for DM-induced BM thickening in various tissues, and 
that antioxidants, specifically MT, were effective scavengers of circulating free radicals 
in affected tissues.  
 In summary, data in the current study strongly support the working hypothesis of 
the current study that 1) PABMs exhibit DM-related thickening in severely diabetic mice 
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and 2) that this structural alteration is mitigated by specific endothelial targeted 
expression of MT. 
 These results offer much more than merely interesting data, and they clearly 
exhibit more than yet another instance of diabetic BM thickening. Because historically 
the lungs have not presented major clinical challenges in DM, experimental designs 
based on this organ have been largely ignored. As a consequence, the concept of diabetic 
pulmonopathy as one of the major chronic complications of DM has not reached the level 
of current conventional wisdom. Nevertheless, data in the current study provide 
unequivocal evidence that at 150 days of age, hyperglycemia-driven oxidative stress 
leads to statistically significant increased true width (+20%) of PABM in severely 
diabetic transgenic mice. More importantly, the study demonstrates that antioxidants 
specifically targeted to the global endothelial cell population completely eliminates 
hyperglycemia-driven PABM thickening and returns their width to below onset control 
levels. This is astonishing and places the PABM in a class of elite BMs including 
glomerular and myocardical capillary BMs that are reduced to normal width and respond 
positively to endothelial antioxidant therapy (Hewitt et al., abstract in press). 
 It is concluded that the current study provides a previously unknown baseline of 
morphometric information on PABM widths in control and severely diabetic transgenic 
mice and establishes a definition of diabetic pulmonopathy as a new and innovative 
chronic complication of diabetes. Moreover our preliminary data demonstrates the 
efficacy of antioxidant therapy on this disease and offers hope for translational studies by 
which this therapeutic modality can become a model for the reduction of the devastating 
consequences of many if not, all chronic complications of DM issues.
  
APPENDIX 
48 
Table 1. Animal genotype, number of animals, number of epoxy blocks sectioned, 
number of micrographs taken, and number of measurements made per micrograph for 
orthogonal intercept calculation of true PABM thickness. 
Genotype Number of Animals Total # of Blocks Total # of Micrographs Average # of PABM measurements 
per micrograph 
Total # of 
PABM 
measurements 
60 Day-Old Mice 
FVB  6  12  120  7.49  899 
OVE  6  12  129  7.78  1,004 
Jtmt  6  12  118  8.58  1,013 
OVEJtmt  6  11  118  8.79  1,038 
TOTAL  24  47  485  8.15  3,954 
150 Day-Old Mice  
FVB  6  12  120 9.7  1,165 
OVE  4  8  80 11.2  896 
Jtmt  7  14  137 8.75  1,199 
OVEJtmt  6  12  120 9.24  1,109 
TOTAL  23  46  457 9.56  4,369 
Numerical data derived from micrographs of 60 and 150 day-old mice, listed by genotype 
with the number of animals used for each group, as well as the total number of blocks 
sectioned, total number of micrographs taken, and the average number of measurements 
per micrograph. The final column lists the total number of micrographs obtained for each 
genotype. 
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Figure 1.  General appearance of 150 day-old mice.  
A) Representative normal (FVB) mouse. FVB and transgenic (Jtmt) 
normal animals similar to this mouse can be identified by the presence of 
normal eyes.  
 B) Representative diabetic (OVE) mouse. OVE and bi-transgenic 
(OVEJtmt) diabetic mice consistently exhibit small eyes as illustrated. 
 
 
 
Table 2. Mean body weight, blood glucose, and HbA1c values from 60 and 150 day-old 
FVB, Jtmt, OVE and OVEJtmt mice ± S.D.  
Genotype Age (days) Body Wt (g) Blood Glucose 
(mgs/dl) 
HbA1c (%) 
FVB  60 21.78 ± 1.69 192.83 ± 21.95 4.30 ± 0.01 
FVB  150 34.80 ± 3.96 198.80 ± 21.71 4.06 ± 0.08 
Jtmt  60 27.21 ± 3.74 194.00 ± 38.59 4.20 
Jtmt  150 28.47 ± 2.86 188.28 ± 31.06 <4.0 
OVE  60 22.87 ± 1.77 644.66 ± 64.19 8.65 ± 0.74 
OVE  150 29.97 ± 2.81 715.50 ± 49.00 10.40 ± 1.43 
OVEJtmt  60 20.96 ± 1.80 610.16 ± 68.16 8.50 ± 1.04 
OVEJtmt  150 25.25 ± 0.69 634.16 ± 86.06 9.68 ± 1.04 
60 and 150 day-old mice listed by genotype and with their associated body weights 
(measured in grams), blood glucose levels (measured in mg/dl), and HbA1c levels 
(represented by percentages). 
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Figure 2.  Toluidine blue stained light micrograph with higher magnification 
transmission electron micrograph inset of terminal respiratory region of 
150 day-old FVB control mouse lung. 
A) Light microscopic image of toluidine blue stained thick section of 
terminal respiratory portion of lung from FVB control mouse. Alveolar 
ducts (AD) and alveolar sacs (AS) dominate the field. Small rectangle 
indicates the area shown by TEM in the inset. x110. 
B) Inset transmission electron micrograph illustrates pulmonary 
components typically located in the small rectangular region shown in 
figure 2A. A rich pulmonary capillary network separated from the air 
space by the respiratory filtration barrier is the primary feature of this 
region of the lung. Intravascular cells include lymphoctyes (L) and 
erythrocytes (Ec) A type I alveolar cell (A2) is located in the respiratory 
septum between alveoli. X2,500. 
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Figure 3.  Transmission electron micrograph of 150 day-old FVB control mouse 
lung. Endothelial cells (En) line the inside of the blood-air barrier. Type I 
alveolar cells (A1) cover its external surface. Pulmonary alveolar 
basement membrane separated these two cells types. A type II alveolar 
cell (A2) is shown in the upper right corner of the micrograph. x16,000.  
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Figure 4.  Transmission electron micrograph of two adjacent respiratory filtration 
barriers in lung of 150 day-old FVB control mouse. Endothelial cells (En) 
line the intravascular surface of the blood-air barrier, while type I alveolar 
cells (A1) line the air space of the barrier. The pulmonary alveolar 
basement membrane (PABM) is located between the two cell types and is 
indicated by the arrowhead. X60,000. 
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Figure 5.  Representative transmission electron micrographs of respiratory filtration 
barriers in 60 day-old FVB, Jtmt, OVE, and OVEJtmt mice. Figures A-D 
illustrate typical blood-air barriers in FVB, Jtmt, OVE, and OVEJtmt mice 
at identical magnifications. Visual observation suggests that pulmonary 
alveolar basement membranes (located between opposing arrowheads) 
exhibit similar widths. x60,000. 
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Figure 6.  Representative transmission electron micrographs of respiratory filtration 
barriers in 150 day-old FVB, Jtmt, OVE, and OVEJtmt mice. Figures A-D 
illustrate typical blood-air barriers in FVB, Jtmt, OVE, and OVEJtmt mice 
at identical magnifications. Preliminary visual observations suggest that 
pulmonary alveolar basement membranes (located between opposing 
arrows are show similar thicknesses, except for the severely diabetic 
(OVE) animals indicated in Figure 5C. x60,000.
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Figure 7. Mean pulmonary alveolar basement membrane thickness in 60 day-old 
mice. Non-transgenic background control mice (FVB), transgenic mice 
overexpressing metallothionein in endothelial cells (Jtmt), transgenic 
diabetic mice (OVE), and bi-transgenic diabetic mice overexpressing 
metallothionein in endothelial cells (OVEJtmt). FVB versus OVEJtmt 
show statistically significant differences. Statistically significant 
difference (P <0.05).  
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Figure 8.  Mean pulmonary alveolar basement membrane thickness in 150 day-old 
mice. Non-transgenic background control mice (FVB), transgenic mice 
overexpressing metallothionein in endothelial cells (Jtmt), transgenic 
diabetic mice (OVE), and bi-transgenic diabetic mice overexpressing 
metallothionein in endothelial cells (OVEJtmt). FVB versus OVE, Jtmt 
versus OVEJtmt and OVE versus OVEJtmt show statistically significant 
differences. Statistically significant difference (P <0.05).  
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Figure 9.  Age-related mean pulmonary alveolar basement membrane thickness in 
60 day-old and 150 day-old mice. Statistical significance is shown 
between OVE 60 and 150 day-old mice (P = 0.01). P value is set at p < 
0.05. 
 
 
 
Table 3. Age-related mean pulmonary alveolar basement membrane thickness in  
60 and 150 day-old mice. 
Genotype Age (Days) Mean width 
+S.D. in 
nanometers 
Age-related 
change in 
thickness 
Age-related 
percentage 
change 
Statistical 
Significance 
(P <0.05) 
FVB  60 49.11 ± 5.13    
FVB  150 48.71 ± 6.63 - 0.4 nm - 0.8% N.S. 
Jtmt  60 50.01 ± 7.38    
Jtmt  150 52.76 ± 4.79 + 2.75 nm + 5.4%  N.S. 
OVE  60 49.37 ± 6.29    
OVE  150 58.42 ± 6.93 + 9.09 nm + 18.3% P = 0.44 
OVEJtmt  60 44.97 ± 4.76    
OVEJtmt  150 47.75 ± 8.01 + 2.78 + 6.1% N.S. 
Numerical comparison of pulmonary alveolar basement membrane thickness in 60 and 
150 day-old non-transgenic background control mice (FVB), transgenic mice (Jtmt), 
transgenic diabetic mice (OVE), and bi-transgenic diabetic mice overexpressing 
metallothionein in endothelial cells (OVEJtmt) ± S.D. 
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Figure 10.  Representative light micrographs of paraffin embedded kidney cortex and 
lung immunohistochemically stained for MTII. 
A) Jtmt kidney. Negative control; primary antibody omitted.  
B) Jtmt kidney 
C) FVB lung. Negative control, primary antibody omitted.   
D) FVB lung.  
E) Jtmt lung. Negative control, primary antibody omitted. 
F) Jtmt lung.  
MT I/II staining was observed in proximal tubules of the kidney. Light 
staining was observed in the alveolar-capillary network of the FVB lung 
and more intense staining was observed in the Jtmt lung. 
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Figure 11.  Average pulmonary MT I/II (µg/mg total tissue protein) in FVB control 
(n=2), Jtmt transgenic (n=2), OVE (n=2) and OVEJtmt (n=2) transgenic 
and bi-transgenic animals. In Jtmt mice, MT I/II was approximately a two-
fold increase over the FVB control. In the OVEJtmt MT I/II measured 
approximately 0.5 fold higher than the FVB control. 
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